All In Biotech

Drug Trial Radar · NCT06146101

RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

A Phase II/III, Randomised, Double-Blind Clinical Trial to Determine the Safety and Efficacy of IHL-42X in Subjects With Obstructive Sleep Apnoea Who Are Intolerant, Non-Compliant, or Naïve to Positive Airway Pressure

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

121

Actual

Start

May 2, 2024

Primary completion

May 20, 2025

Study completion Jul 27, 2025

Sponsor

Lead sponsor
Incannex Healthcare LtdIndustry
Sponsor type
Industry
First posted
Nov 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomised, double-blind phase II/III clinical trial is to determine the safety and efficacy of IHL-42X in subjects with obstructive sleep apnoea who are intolerant, non-compliant, or naïve to positive airway pressure. Phase II study will be a 4-week dose-finding study comparing two dose strengths of IHL-42X to placebo. The optimal dose strength will be selected based on comparing the safety and efficacy of the two IHL-42X dose strengths to placebo over a 4-week treatment period. The three treatment groups are; IHL-42X Low dose (2.5mg dronabinol, 125mg acetazolamide), IHL-42X High dose (5mg dronabinol, 250mg acetazolamide) and Placebo. Each treatment group will enrol approximately 40 patients per treatment arm, for a total of approximately 120 patients. The safety and efficacy results of the Phase II study will be used to select the dose strength of IHL-42X and corresponding doses of dronabinol and acetazolamide in Phase III. Phase III study will use the optimal dose strength of IHL-42X identified in Phase II and will be compared to the component active pharmaceutical ingredients at equivalent dose strengths to those found in the IHL-42X optimal dose strength and placebo over 52 weeks. The four treatment groups are; IHL-42X (optimal dose from Phase II), Acetazolamide (equivalent dose strength to that in the IHL-42X optimal dose strength), Dronabinol (equivalent dose strength to that in the IHL-42X optimal dose strength) and placebo. The treatment groups will enrol approximately 165 patients in IHL-42X, approximately 55 patients in dronabinol, approximately 55 in acetazolamide, and approximately 165 in placebo, for a total of approximately 440 patients.

Conditions

  • Obstructive Sleep Apnea

Interventions

  • IHL-42X Low DoseDrug

    Softgel capsule

  • IHL-42X High DoseDrug

    Softgel capsule

  • PlaceboDrug

    Softgel capsule

  • IHL-42X (Optimal Dose)Drug

    Softgel capsule

  • DronabinolDrug

    Softgel capsule

  • AcetazolamideDrug

    Softgel capsule

  • PlaceboDrug

    Softgel capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in apnea-hypopnea index (AHI)Time frame: 4 weeks
  2. Change in apnea-hypopnea index (AHI)Time frame: 52 weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Exalt Clinical Research

    Chula Vista, California

  • CenExel CNS- Los Alamitos

    Long Beach, California

  • Pacific Clinical Research Medical Group

    Upland, California

  • Clinical Neuroscience Solutions, Inc. (CNS Healthcare of Jacksonville)

    Jacksonville, Florida

  • Clinical Neuroscience Solutions, Inc. (CNS Healthcare of Orlando)

    Orlando, Florida

  • Teradan Clinical Trials

    Valrico, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

  • NeuroTrials Research, Inc.

    Atlanta, Georgia

  • Tandem Clinical Research, LLC

    Marrero, Louisiana

  • Centennial Medical Group

    Elkridge, Maryland

  • Meridian Clinical Research, LLC

    Rockville, Maryland

  • Henderson Clinical Trials,LLC

    Henderson, Nevada

  • Advanced Respiratory and Sleep Medicine, PLLC

    Huntersville, North Carolina

  • CTI Clinical Trial and Consulting Services

    Cincinnati, Ohio

  • Intrepid Research

    Cincinnati, Ohio

  • Velocity Clinical Research - Anderson

    Anderson, South Carolina

  • Velocity Clinical Research - Greenville

    Greenville, South Carolina

  • Clinical Neuroscience Solutions, Inc. (CNS Healthcare of Memphis)

    Memphis, Tennessee

  • FutureSearch Trials

    Austin, Texas

  • FutureSearch Trials of Dallas, LP

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.